{"id":2539,"date":"2024-10-30T18:43:24","date_gmt":"2024-10-30T17:43:24","guid":{"rendered":"https:\/\/oximio.com\/?post_type=oximio-resources&p=2539"},"modified":"2024-10-30T18:43:25","modified_gmt":"2024-10-30T17:43:25","slug":"sickle-cell-disease-clinical-trials-africas-solution","status":"publish","type":"oximio-resources","link":"https:\/\/oximio.com\/resources\/sickle-cell-disease-clinical-trials-africas-solution\/","title":{"rendered":"Sickle Cell Disease Clinical Trials: Africa\u2019s Solution\u00a0"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Sickle cell disease is known to be a global disease burden. Reportedly, more than 66% of the 120 million people affected worldwide by sickle cell disease live in Africa and approximately 1000 children are born with the disease every day in Africa, making it the most prevalent genetically acquired disease in the region. Whilst we have learned a significant amount about the disease and how to manage its symptoms, further research and clinical trials are essential if we are to find better treatments and help those with the disease. \u00a0<\/p>

In this article, we look at what the disease is, how it affects those individuals with the disease, and what makes Africa a key location for sickle cell disease clinical trials.<\/strong><\/p>

What is Sickle Cell Disease?<\/h2>

Sickle cell disease is a genetically acquired blood disorder affecting the haemoglobin, a molecule that helps carry oxygen around the body within red blood cells. This mutation causes the red blood cells to become rigid, sticky, and prone to forming a sickle shape. As a result, this can lead to the obstruction of blood flow resulting in a variety of complications including organ damage, anaemia, severe pain and leaving those with the disease at a greater risk of infection when their natural defence mechanisms are inadequate to protect them.<\/p>

A Global Disease Burden<\/h2>

SCD affects millions of individuals worldwide, predominantly those with ancestry from regions where malaria is or was endemic. It is estimated that around 300,000 babies are born with SCD each year, with most of these cases occurring in sub-Saharan Africa. The disease is also prevalent in other parts of the world, such as the Middle East, India, the Mediterranean, and regions with a substantial concentration of African originated populations, including the United States.<\/p>

Clinical Trials and Research<\/h2>

Progress in understanding sickle cell disease and effectively addressing its symptoms has elevated the standard of living for individuals affected by this condition. Nevertheless, there remains an imminent requirement for new remedies that target the fundamental root of the ailment. Throughout the years, multiple clinical experiments and investigative attempts have concentrated on the disease, exploring innovative treatments.<\/p>

Treatments such as stem cell transplantation is believed to offer a potential cure but usually considered only for those who have severe sickle cell disease complications.<\/p>

Africa: The Optimum Location for Sickle Cell Disease Clinical Trials<\/h2>

With about 80% of sickle cell disease cases occurring in sub-Saharan Africa makes it the ideal location to conduct clinical trials and research studies. Several factors contribute to Africa\u2019s significance in the quest for new treatments:<\/p>